Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

NCT00483262 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CCI-779
DRUG: Bortezomib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]